Loading
A phase 3 trial of Sunvozertinib, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, active and no longer recruiting.
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) is a phase 3 interventional study registered as NCT05668988 by Dizal Pharmaceuticals, with 324 participants enrolled, started 2022-12-13 and due to reach its primary completion in 2026-01-16. Interventions recorded: sunvozertinib, Pemetrexed+carboplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Dizal Pharmaceutical, Pemetrexed, Carboplatin, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/